The prevention and treatment of candidal infections of the oral cavity, oesophagus and intestinal tract. The suspension provides effective prophylaxis against oral candidosis in those born of mothers with vaginal candidosis.
The FDA has approved Fycompa (perampanel) CIII Oral Suspension, from Eisai, as adjunctive therapy for the treatment of partial-onset seizures...
Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Group, announced that MTPC obtained the regulatory approval of Radicut Oral Suspension 2.1% (generic name: edaravone) for the treatment of patients with amyotrophic lateral sclerosis (ALS) from the Ministry of Health, Labour and Welfare on December 23, 2022.
Neos Therapeutics, Inc. announced that the FDA has approved Adzenys ER (amphetamine) Extended-Release Oral Suspension. Neos Therapeutics is the only...
Eton Pharmaceuticals, Inc., has announced the FDA has accepted for filing the company’s new drug application (NDA) for ET 104 ( zonisamide oral suspension).
Novartis announced that the FDA has approved Jadenu (deferasirox) tablets, a new oral formulation of Exjade (deferasirox) tablets for oral...
ITF Pharma announced that the FDA has approved Tiglutik (riluzole) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS)....
Eton Pharmaceuticals, Inc a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has submitted a new drug application (NDA) for zonisamide oral suspension, previously known as the company’s ET 104 product candidate, to the FDA for the treatment of partial seizures in patients with epilepsy.
The FDA has approved a label expansion for ibrutinib (Imbruvica) with an oral suspension formulation for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia, and chronic graft-versus-host disease (cGVHD) after failure on at least 1 line of systemic therapy